-
RNA Pol II Loss Triggers Regulated Apoptosis
2026-08-17
Harper et al. show that RNA polymerase II inhibition kills cells through an active apoptotic program triggered by loss of hypophosphorylated RNA Pol IIA, rather than through passive depletion of transcripts and proteins. Their functional-genomics framework defines the Pol II degradation-dependent apoptotic response and provides a way to reinterpret the cytotoxicity of otherwise unrelated anticancer drugs.
-
Niclosamide Workflows for STAT3 Cancer Research
2026-08-17
Build more informative Niclosamide experiments by pairing STAT3 Tyr-705 measurements with apoptosis, cell-cycle, NF-κB, and viability readouts. This workflow also shows how ATRX-stratified glioma models can generate disciplined combination hypotheses without overstating evidence from unrelated inhibitor classes.
-
Flavopiridol in ER Stress Assay Design
2026-08-16
Flavopiridol and L868275 are examined here as mechanistic tools for separating CDK-dependent cell-cycle effects from ER-stress-driven intestinal stem-cell injury. This assay-focused perspective connects pan-CDK biology with GRP78/ATF6/CHOP and p44/42 MAPK readouts while defining practical limitations.
-
Concanamycin A and the Lysosomal Stress Switch
2026-08-15
Concanamycin A is more than a lysosomal acidification reagent: it is a precise way to test whether V-ATPase-dependent adaptation determines tumor-cell survival under metabolic stress. Anchored to the 2025 TCF25 study, this article presents a translational framework for connecting proton transport, autophagy, lysosomal death, and invasion phenotypes.
-
AP20187: From Dimerization to Translational Control
2026-08-14
AP20187 is more than an inducible research reagent: it is a controllable interface between engineered protein architecture and translational biology. This thought-leadership article examines how chemical inducer of dimerization systems can help researchers interrogate tumor-microenvironment signaling, regulated cell therapy, and metabolic control. Anchored by evidence that senescent cancer-associated fibroblasts suppress natural killer cell activity in breast cancer, it outlines experimental design principles, handling guidance, competitive considerations, and the limitations that must be addressed before conditional signaling platforms can support higher-confidence translational decisions.
-
Zoledronic Acid: Designing Mechanism-First Assays
2026-08-14
Explore how Zoledronic Acid assays can move beyond viability measurements toward causal interpretation in cancer and bone research. This guide integrates product-specific handling with assay-design lessons from a mechanistic psoriasis study.
-
Cyclophosphamide: Research Workflows and Optimization
2026-08-13
Build more reproducible cancer and immunology experiments with Cyclophosphamide, from 9L gliosarcoma apoptosis assays to immune-cell depletion models. This guide connects formulation, timing, controls, and readouts with practical comparisons to topotecan-based DNA-damage studies.
-
Reelin–SFK Signaling in Ketamine Response
2026-08-13
The reference study identifies Reelin–Apoer2–Src family kinase signaling as a permissive requirement for ketamine-induced hippocampal plasticity and antidepressant-like behavioral responses. By combining genetic deletion, pharmacological perturbation, electrophysiology, and biochemical analysis, it offers a mechanistic framework for understanding why some treatment-resistant depression models fail to respond to ketamine.
-
Light, Brassinolide, and Arabidopsis Root Growth
2026-08-12
The reference study separates the effects of light, endogenous brassinosteroids, and exogenous brassinolide on Arabidopsis seedling root growth using complementary genetic and chemical perturbations. Its central finding is that light generally promotes primary root elongation, whereas endogenous and applied brassinosteroids suppress it in largely independent ways, with brassinazole producing strongly context-dependent effects.
-
Abiraterone acetate in 3D Prostate Cancer Assays
2026-08-12
Build more translational prostate cancer research workflows by pairing a CYP17 inhibitor with patient-derived 3D spheroids. This guide covers compound preparation, dose design, pathway-aware readouts, and troubleshooting when abiraterone exposure produces little measurable viability change.
-
Entecavir Workflows for HBV Replication Studies
2026-08-11
Build reproducible HBV replication assays around Entecavir, from nanomolar dose-response testing to sequence-based resistance surveillance. The workflow connects cell-based potency, cccDNA-oriented readouts, and treatment-history stratification for wild-type and lamivudine-resistant models.
-
Sulfaphenazole-Derived Sulfonamides Against M. tuberculosis
2026-08-11
The reference study systematically optimized sulfaphenazole-derived sulfonamides to retain antimycobacterial activity while reducing CYP2C9 inhibition, identifying compound 10d as a leading in vitro example. Its structure–activity relationship findings illustrate how targeted modification of the pyrazole-associated phenyl region can improve the balance between antibacterial efficacy and drug-interaction risk.
-
MK-4827 (Niraparib) PARP Research Workflows
2026-08-10
Build reproducible DNA damage repair inhibition assays with MK-4827 (Niraparib), from BRCA-mutant viability studies to radiosensitization and hepatocellular carcinoma models. The workflow also translates spliceosome biology into practical response-stratification experiments without assuming that every PARP inhibitor model is BRCA dependent.
-
MDV3100: From AR Biology to Translational Strategy
2026-08-09
MDV3100 (Enzalutamide) is more than a second-generation androgen receptor antagonist: it is a mechanistic probe for ligand-dependent AR signaling, apoptosis, nuclear trafficking, and treatment resistance. This thought-leadership article connects prostate cancer research with emerging AR biology in triple-negative breast cancer while defining the experimental controls needed for credible translation.
-
ECE-1c, CK2, and Cisplatin Resistance in Lung Cancer
2026-08-08
Almarza et al. identify ECE-1c Lys-6 as a stability-regulating residue that links CK2 signaling to stemness, cisplatin resistance, and invasive behavior in NSCLC cells. The study supports an ET-1-independent model in which stabilized ECE-1c contributes to aggressive phenotypes and positions phospho-ECE-1c and silmitasertib-sensitive CK2 signaling as testable translational hypotheses.